By [Your Name/Journalist Name]
October 26, 2026
In a significant development for the management of relapsing multiple sclerosis (MS), the Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib has demonstrated superior clinical efficacy compared to the standard-of-care therapy, teriflunomide (Aubagio). Data from two identical, large-scale Phase III trials—REMODEL-1 and REMODEL-2—reveal that the twice-daily oral treatment not only reduces relapse rates but also offers a favorable safety profile, notably lacking the liver toxicity signals that have hindered other candidates in the BTK inhibitor class.
The findings, presented at MSToronto2026, the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), were simultaneously published in The Lancet. These results position remibrutinib as a potentially transformative option for the estimated 2.8 million people living with MS worldwide.
The Core Data: Superiority in Relapse Reduction
The primary objective of the REMODEL studies was to evaluate whether remibrutinib could outperform teriflunomide in curbing disease activity in patients with relapsing MS. The results were consistent across both cohorts.
In REMODEL-1, patients receiving 100 mg of remibrutinib twice daily achieved an annualized relapse rate (ARR) of 0.073, compared to 0.112 for those on teriflunomide. This represents a rate ratio (RR) of 0.648 (95% CI 0.453–0.927; P=0.018). The results in REMODEL-2 were similarly robust, with an ARR of 0.080 for remibrutinib versus 0.116 for teriflunomide (RR 0.688; P=0.034).
Dr. Heinz Wiendl, lead investigator of the University of Freiburg, Germany, highlighted the clinical significance of these numbers, noting that the relapse rate observed with remibrutinib equates to roughly one relapse every 13 years—a metric that suggests a high level of disease control for patients who have historically struggled with the unpredictable nature of MS flare-ups.
A New Frontier in Disease Monitoring: Lesions and NfL
Beyond simple relapse counts, the investigators examined biomarkers and imaging data to determine the drug’s impact on subclinical disease activity. The results painted a compelling picture of neuroprotection.
T2 and Gadolinium-Enhancing Lesions
The reduction in new and enlarging T2 lesions—a standard marker of inflammatory disease activity—was striking. In both trials, remibrutinib outperformed teriflunomide by 65% to 70%. Furthermore, gadolinium-enhancing lesions, which indicate active inflammation and blood-brain barrier disruption, were “massively reduced” in patients taking remibrutinib, according to Wiendl.
Neurofilament Light Chain (NfL)
The study also measured serum neurofilament light chain (NfL) levels, an emerging and sensitive biomarker for axonal injury. At 12 months, NfL levels were significantly lower in the remibrutinib groups compared to the teriflunomide groups in both trials. This reduction suggests that remibrutinib may provide a degree of neuroprotection that extends beyond the control of inflammatory relapses, potentially slowing the long-term, irreversible damage associated with MS.
Disability Progression: The Long-Term Outlook
While relapses are a primary concern for patients, the prevention of long-term disability progression is the ultimate goal of MS therapy. The pooled analysis of the REMODEL trials showed a 3-month confirmed disability progression (CDP) rate of 11.7% for remibrutinib versus 14.1% for teriflunomide. While the 3-month result did not reach statistical significance (HR 0.80; P=0.090), the 6-month CDP data told a more favorable story.
At the 6-month mark, the rate of confirmed disability progression was 7.7% for remibrutinib and 10.5% for teriflunomide, representing a statistically significant risk reduction (HR 0.70; 95% CI 0.51–0.98; P=0.038). This outcome provides clinicians with evidence that remibrutinib may play a meaningful role in delaying the physical decline associated with disease progression.
Addressing the "Liver Safety" Question
The BTK inhibitor class has faced intense scrutiny regarding liver toxicity. Several other experimental BTK inhibitors in the MS space have seen clinical trials paused or terminated due to concerns regarding drug-induced liver injury (DILI).
Remibrutinib’s profile appears to be distinct in this regard. During the REMODEL trials, researchers saw no liver safety signals. While some patients experienced transient, infrequent elevations in liver enzymes, these were typically reversible and did not follow the patterns seen with other agents in the class. Most importantly, there were no cases that met the criteria for Hy’s Law, which serves as a definitive red flag for potential fatal drug-induced liver injury.
“We haven’t seen really a liver signal at all,” Dr. Wiendl stated during the presentation. This distinction could prove to be a major competitive advantage for the drug, particularly as regulators weigh the benefit-risk profiles of incoming MS therapies.
Safety Profile and Adverse Events
The overall safety profile of remibrutinib in the REMODEL trials was largely consistent with its established use in other indications. The drug is already approved in a 25-mg formulation (under the brand name Rhapsido) for chronic spontaneous urticaria and symptomatic dermographism.
The most frequently reported adverse events included:
- Upper respiratory tract infections: 13.1% (remibrutinib) vs 13.7% (teriflunomide)
- Nasopharyngitis: 9.1% vs 12.3%
- Diarrhea: 8.3% vs 10.9%
- Alopecia: 5.8% vs 13.5%
One notable finding was a higher incidence of bleeding events in the remibrutinib group (12.7%) compared to the teriflunomide group (6.7%). Dr. Wiendl characterized these as a "class effect" of BTK inhibitors, noting that the events were generally mild, transient, and confined to the skin.
Regarding mortality, there were two deaths in the remibrutinib cohort; however, both were investigated and determined to be unrelated to the study drug—one involved carbon monoxide poisoning (suicide ruled out) and the other was a suicide in a patient with a documented history of psychiatric illness. Adverse events leading to treatment discontinuation were lower in the remibrutinib group (3.1%) than in the teriflunomide group (5.8%), suggesting better overall tolerability.
Implications and Future Outlook
The REMODEL trials involved a diverse group of patients between the ages of 18 and 55, all with evidence of recent disease activity and an Expanded Disability Status Scale (EDSS) score between 0 and 5.5. With over 2,000 participants combined, the data is robust enough to provide a clear picture of how the drug functions in a real-world clinical population.
Novartis, the manufacturer of remibrutinib, has confirmed its intention to seek regulatory approval for the drug in relapsing MS on a global scale. Given the drug’s high efficacy in reducing both relapses and lesion activity, combined with a cleaner safety profile regarding liver function, remibrutinib is poised to become a significant challenger to existing oral MS therapies.
Beyond MS, the drug is currently being investigated for its potential in other immune-mediated conditions, including hidradenitis suppurativa and various food allergies. As the medical community awaits further long-term data, the results from REMODEL-1 and REMODEL-2 offer a glimmer of hope for patients seeking more effective, safer, and more convenient ways to manage the complexities of multiple sclerosis.
For the millions of patients currently navigating the uncertainty of relapsing MS, these findings represent more than just statistics; they offer the prospect of a future where disease progression can be more effectively halted, and the frequency of debilitating relapses can be significantly diminished.
